Oncology · Multiple MyelomaRegulatory Approvalcommercialnear-term

Cipla's Lenalidomide ANDA210435 Receives Abbreviated Approval from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Cipla Ltd.7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:32:33 AM

Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Cipla's abbreviated approval for Lenalidomide introduces a new competitor in the oncology market, which could disrupt pricing and market dynamics. Pharma strategy teams should closely monitor Cipla's market entry and pricing strategies to assess the impact on existing products and market share. Regulatory context from FDA (FDA AP — LENALIDOMIDE (SUPPL)) supports the near-term read. Assessment grounded in 27 ranked evidence items (14 high-relevance).

Strategic Assessment

Cipla's entry could pressure pricing and market share for current Lenalidomide suppliers, necessitating strategic adjustments. The strongest clinical anchor is A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma (ClinicalTrials.gov), entity match (lenalidomide). In Oncology · Multiple Myeloma, 7 regulatory and 4 competitive items passed relevance filtering for Cipla.

Competitive Pressure

The most relevant competitive pressure comes from Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval (Humanexa Signals) — entity match (lenalidomide). Secondary pressure from FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC). This approval allows Cipla to enter the market for Lenalidomide, increasing competition against existing branded therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LENALIDOMIDE (SUPPL) (FDA). Entity match (cipla); Regulatory pathway relevance (nda). The approval signifies compliance with FDA requirements, but it does not introduce significant regulatory changes for existing products.

Key Opportunities

The entry of Cipla into the Lenalidomide market may lead to increased competition, potentially driving down prices and affecting revenue for current suppliers.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Upside for Cipla may improve if A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Ritu (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Cipla may improve if Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timing and pricing strategies from Cipla and responses from competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LENALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LENALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (cipla); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LENALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (lenalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LENALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (lenalidomide); Regulatory pathway relevance (nda)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.govhigh relevance
Entity match (lenalidomide)
FDA document
View source
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
ClinicalTrials.govhigh relevance
Entity match (lenalidomide)
FDA document
View source
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
ClinicalTrials.govhigh relevance
Entity match (lenalidomide)
FDA document
View source
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Ritu
ClinicalTrials.govhigh relevance
Entity match (lenalidomide)
FDA document
View source
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval
Humanexa Signalshigh relevance
Entity match (lenalidomide)
FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sandoz Receives FDA Approval for Enzalutamide ANDA216068
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

RBMS1 enhances PDPK1 mRNA stability to promote multiple myeloma malignancy and M2 macrophage polarization.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Cipla
Lenalidomide

Commercial impact

medium

The entry of Cipla into the Lenalidomide market may lead to increased competition, potentially driving down prices and affecting revenue for current suppliers.

Regulatory impact

low

The approval signifies compliance with FDA requirements, but it does not introduce significant regulatory changes for existing products.

What to watch

Monitor market entry timing and pricing strategies from Cipla and responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.